A challenge for utilizing ADCs for pediatric solid tumors is that there are few solid tumor correlates of the surface antigens like CD19, CD22, and CD30 (TNFRSF8) that show high expression within a restricted set of normal cell types and that are shared between pediatric and adult leukemias and lymphomas. Here, CD22 is linked to leukemia.